AJ1-11095

N/A

Report date: 2026/05/13 20:02:10
NMEFirst In Class

Base Information

Drug NameAJ1-11095
Drug Alias NameAJ1-11095
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitors
TargetsTyrosine-protein kinase JAK2
Therapy Area/IndicationsPrimary MyelofibrosisMyeloproliferative DisordersThrombocythemia, Essential +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAjax Therapeutics IncSchrödinger Inc
China Registration ClassN/A

Develop Information

Active CompaniesAjax Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisMyeloproliferative DisordersThrombocythemia, Essential +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A